Rob Quinn, from Silence Therapeutics (LON:SLN) pitches the company to investors at the Proactive One2One Virtual Event. Silence develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.
Silence Therapeutics - Proactive One2One Virtual Event
Quick facts: Silence Therapeutics PLC
Price: 435 GBX
Market Cap: £360.29 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE